A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab VersusIbrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia(CLL)

Protocol number: A041202

Projected enrollment dates: September 2014 to March 2018

Official study title: A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT01886872

You are here

A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab VersusIbrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia(CLL)